TCR2 Therapeutics Inc. Stock News

TCR2 Therapeutics Inc. (NASDAQ:TCRR) saw a large decrease in short interest in October. As of October 29th, there was short interest totalling 1,300,000 shares, a decrease of 15.0% from the October 14th total of 1,530,000 shares. Based on an average daily volume of 778,700 shares, the days-to-cover ratio is currently 1.7 days. Approximately 3.6% of []

TCR2 Therapeutics Inc. (NASDAQ:TCRR)s traded shares stood at 0.85 million during the last session. At the close of trading, the stocks price was $5.93, to imply a decrease of -2.47% or -$0.15 in intraday trading. The TCRR shares 52-week high remains $35.86, putting it -504.72% down since that peak but still an impressive -0.84% since After This Weeks -13.93% Loss In TCR2 Therapeutics Inc. (NASDAQ: TCRR), We Just Learned Something New Read More »

Northern Trust Corp raised its holdings in TCR2 Therapeutics Inc. (NASDAQ:TCRR) by 0.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 331,163 shares of the companys stock after buying an additional 1,738 shares during the period. Northern Trust Corp owned 0.87% of TCR2 Therapeutics []

TCR2 Therapeutics (NASDAQ:TCRR) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. Its product candidate includes TC-210, []

TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock analysts at Wedbush boosted their FY2021 earnings per share (EPS) estimates for shares of TCR2 Therapeutics in a note issued to investors on Wednesday, November 10th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($2.69) per share for the year, up from their previous forecast of []

TCR2 Therapeutics Inc. (NASDAQ:TCRR) Equities researchers at SVB Leerink boosted their FY2021 earnings per share (EPS) estimates for shares of TCR2 Therapeutics in a report released on Wednesday, November 10th. SVB Leerink analyst J. Chang now anticipates that the company will post earnings of ($2.64) per share for the year, up from their previous []

The stock price of TCR2  Therapeutics (Nasdaq: TCRR) increased by over 1% pre-market today. This is why it happened.

CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from c

The stock price of TCR2 Therapeutics Inc (NASDAQ: TCRR) fell by over 30% during intraday trading. This is why it happened.

- Clinical activity observed in all three mesothelin-expressing tumor types treated

CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from

CAMBRIDGE, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from c

CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from c